#1 Clinical Trials Search in Europe

Digitoxin

Digitoxin, a cardiac glycoside traditionally used for heart conditions, is now being investigated for its potential benefits in treating cystic fibrosis (CF). This article delves into recent clinical trials that explore the effects of digitoxin on inflammation and lung function in CF patients, offering hope for new treatment options in this challenging genetic disorder.

Table of Contents

What is Digitoxin?

Digitoxin is a medication that is being studied for its potential benefits in treating cystic fibrosis (CF). It belongs to a class of drugs known as cardiac glycosides, which are traditionally used to treat heart conditions. However, recent research has shown that digitoxin may have anti-inflammatory properties that could be beneficial for CF patients.[1]

Cystic Fibrosis and Digitoxin

Cystic fibrosis is a genetic disorder that affects the lungs and other organs. It causes thick, sticky mucus to build up, leading to frequent lung infections and breathing difficulties. Researchers are exploring whether digitoxin can help reduce inflammation in the lungs of CF patients, potentially improving their lung function and quality of life.[1]

Clinical Trial Details

A Phase II clinical trial was conducted to study the effects of digitoxin on cystic fibrosis patients. This trial was designed to measure the anti-inflammatory effects of digitoxin and how the body processes the drug. Here are some key details about the study:[1]

  • The trial was randomized, double-blind, and placebo-controlled.
  • It involved 24 patients with mild to moderate cystic fibrosis lung disease.
  • Patients were divided into three groups of 8 people each.
  • The study lasted for 28 days.

Dosage and Administration

In the clinical trial, digitoxin was administered in two different doses:[1]

  • Low dose: 0.05 mg of digitoxin given once daily for 28 days
  • Higher dose: 0.1 mg of digitoxin given once daily for 28 days
  • A placebo group received a dummy pill daily for 28 days

Primary Outcomes

The main goals of the study were to measure the effects of digitoxin on two important markers of inflammation in CF patients:[1]

  1. IL-8 (Interleukin 8) levels in sputum: IL-8 is a protein that attracts inflammatory cells to the lungs. The study measured IL-8 levels in the sputum (mucus coughed up from the lungs) of patients over 42 days.
  2. Neutrophil counts in sputum: Neutrophils are white blood cells that fight infection but can also contribute to inflammation. The study counted these cells in patients’ sputum over 42 days.

For both measurements, the researchers looked at the changes between the start of the treatment (Day 1) and the end of the treatment period (Day 28).

Secondary Outcomes

The study also looked at several other important factors:[1]

  • Pharmacokinetics of digitoxin: This means how the body processes the drug. The researchers measured digitoxin levels in patients’ blood at various points during the study.
  • Lung function: The study measured changes in FEV1 (Forced Expiratory Volume in 1 second), which is a measure of how well the lungs are working.
  • White blood cell count: This can be an indicator of inflammation in the body.
  • C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR): These are blood tests that can indicate levels of inflammation in the body.

Safety Considerations

The researchers closely monitored the safety of digitoxin during the trial:[1]

  • They performed ECG (electrocardiogram) tests to check for any effects on heart rhythm.
  • They checked patients’ sputum for any changes in bacterial growth, especially looking for multiple drug-resistant bacteria or a type of bacteria called B. cepacia.

The study reported that there were no significant changes in ECG readings and no concerning changes in sputum bacteria during the trial.

Quality of Life Assessment

The researchers used a special questionnaire called the Cystic Fibrosis Questionnaire-Revised (CFQ-R) to measure how the treatment affected patients’ quality of life. This questionnaire looks at various aspects of life with CF, including physical functioning, emotional state, social life, and symptoms.[1]

Genetic Expression Study

As part of the study, researchers also collected nasal epithelial cells (cells from the lining of the nose) from some patients. They used these cells to study how digitoxin affects gene expression – in other words, which genes are turned on or off by the drug. This information could help researchers understand more about how digitoxin works in CF patients.[1]

In conclusion, this clinical trial provides valuable information about the potential use of digitoxin in treating cystic fibrosis. While more research is needed to fully understand its effects and determine if it’s safe and effective for widespread use, these results offer hope for new treatment options for CF patients.

Aspect Details
Study Design Randomized, double-blind, placebo-controlled trial
Participants 24 patients with mild to moderate cystic fibrosis lung disease
Treatment Groups 0.05 mg digitoxin, 0.1 mg digitoxin, placebo (8 patients each)
Duration 28 days of treatment, 42 days total study period
Primary Outcomes IL-8 levels and neutrophil counts in induced sputum
Secondary Outcomes Serum digitoxin levels, lung function (FEV1), quality of life, safety indices
Additional Measures Gene expression in nasal epithelial cells, inflammatory markers (CRP, ESR)
Safety Monitoring ECG readings, sputum microbiology, white blood cell count

FAQ

  • What is the main purpose of the clinical trial using digitoxin for cystic fibrosis? The main purpose of the clinical trial is to measure the anti-inflammatory effects of digitoxin on IL-8 (a type of inflammatory protein) and neutrophil counts in the sputum of stable cystic fibrosis patients. The study also aims to understand how digitoxin is processed in the body of CF patients.
  • How is the digitoxin trial designed? The trial is designed as a randomized, double-blind, placebo-controlled study. It involves 24 patients divided into three groups of 8 each, receiving either 0.05 mg digitoxin, 0.1 mg digitoxin, or a placebo daily for 28 days.
  • What are the primary outcomes measured in the digitoxin trial? The primary outcomes measured are the effects of digitoxin on IL-8 levels and neutrophil counts in induced sputum of CF patients. These measurements are taken at various time points throughout the 42-day study period.
  • Are there any safety measures in place during the digitoxin trial? Yes, the trial includes several safety measures. These include monitoring changes in lung function (FEV1), white blood cell count, ECG readings, and sputum microbiology. The study also assesses quality of life using a CF-specific questionnaire.
  • What additional information is being collected in the digitoxin trial? The trial also collects data on the pharmacokinetics of digitoxin in serum, changes in inflammatory markers like C-reactive protein and erythrocyte sedimentation rate, and gene expression changes in nasal epithelial cells before and after treatment.

Ongoing Clinical Trials on Digitoxin

  • Study of Digitoxin with Chemotherapy for Patients with Inoperable Pancreatic Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Sweden

Glossary

  • Digitoxin: A cardiac glycoside medication traditionally used to treat heart conditions, now being studied for its potential anti-inflammatory effects in cystic fibrosis.
  • Cystic Fibrosis (CF): A genetic disorder that affects the lungs, pancreas, and other organs, causing thick, sticky mucus to build up and leading to infections and breathing problems.
  • IL-8 (Interleukin 8): A type of protein involved in inflammation, particularly in attracting neutrophils to sites of infection or injury.
  • Neutrophils: A type of white blood cell that helps fight infections and is often elevated in inflammatory conditions.
  • Sputum: A mixture of saliva and mucus coughed up from the respiratory tract, often used to diagnose or monitor lung conditions.
  • FEV1 (Forced Expiratory Volume in 1 second): A measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • Pharmacokinetics: The study of how a drug is processed by the body, including its absorption, distribution, metabolism, and excretion.
  • ECG (Electrocardiogram): A test that records the electrical activity of the heart, used to monitor for potential side effects of medications on heart function.
  • C-reactive protein (CRP): A protein produced by the liver in response to inflammation, used as a marker of overall inflammation in the body.
  • Erythrocyte Sedimentation Rate (ESR): A blood test that measures how quickly red blood cells settle in a test tube, used as a general marker of inflammation.

References

  1. https://clinicaltrials.gov/study/NCT00782288